Wire report
New weight-loss shot appears to outperform other obesity drugs on market
Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced on Thursday. The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lb (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss. Continue reading...
coverage / Wire report
Get updates, read source context, send useful records, share the story, or support the reporting work from the reading page.
Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced on Thursday. The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lb (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss. Continue reading...
Check the original link, updates, and responses when a detail is contested.
Open topic or search related wording such as records, sources, agencies, dates, and locations.
What happened
According to The Guardian’s linked item, New weight-loss shot appears to outperform other obesity drugs on market, Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced on Thursday. The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lb (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss. Continue reading…
Context
The development sits in VINI’s Science coverage for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The linked item is dated 2026-05-21T16:50:23+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: New weight-loss shot appears to outperform other obesity drugs on market via The Guardian. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
Keep following
This file can keep developing
vininews.com uses reader tips, public records, right-of-reply requests, corrections, and follow-up reporting to keep important stories current.
Support and subscriptions never buy coverage, placement, suppression, or corrections.
This VINI report keeps the original publisher link available and does not republish third-party article bodies without rights clearance. 1 reference listed.
Source links
- New weight-loss shot appears to outperform other obesity drugs on marketThe Guardian - 2026-05-21T16:50:23+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.
No approved comments yet.
Substantive, civil comments can be submitted by approved account holders.